论文部分内容阅读
麦迪霉素(Medemycin)是大环内脂类的一种新抗生素,其作用与红霉素相类似。其抗菌谱主要为革兰氏阳性球菌,主要是通过抑制细菌体内蛋白质合成,干扰细菌核糖体肽基的转移而引起抗菌的作用。其优点是不易产生诱导耐药性。口服剂型已用于临床治疗呼吸道及一般化脓性感染,具有吸收快、血清浓度高和毒性低的优点。为了在短期内能提高其血清浓度,以治疗急性重的感染和抢救重症患者,四川抗菌素工业研究所已试制成麦迪霉素酒石酸盐静脉滴注剂型。本文报道我们近期以此剂型治疗化脓性感染性疾病99例结果。 一、一般资料 随机选择呼吸道感染疾患及其它化脓性感染病人99例,男性54例,女性45例;年龄一岁半至六十九岁,其中十二岁以下儿童18例,81例均为成人。 二、治疗方法 1.抗菌药物:麦迪霉素酒石酸盐及其冷冻干燥制剂均由四川抗菌素研究所提供,分为两组,(1)麦迪霉素酒石酸盐组(酒石酸
Medemycin is a new macrolide antibiotic that acts like erythromycin. The antibacterial spectrum is mainly Gram-positive cocci, mainly by inhibiting bacterial protein synthesis, interfering with bacterial ribosomal peptide-based transfer caused by antimicrobial effect. Its advantage is not easy to produce induced drug resistance. Oral dosage forms have been used for clinical treatment of respiratory and general purulent infections, with the advantages of fast absorption, high serum concentration and low toxicity. In order to increase its serum concentration in the short term to treat acute severe infections and rescue critically ill patients, the Sichuan Institute of Antibiotics has tried to make an intravenous injection of midecamycin tartrate. This article reports the results of 99 cases of suppurative infectious diseases treated with this dosage form recently. First, the general information Randomly selected 99 cases of respiratory tract infection and other purulent infections in patients, 54 males and 45 females; aged from one year and a half years to 69 years, of which 18 children under the age of 12, 81 were adults . Second, the treatment 1. Antimicrobial drugs: midecamycin tartrate and its freeze-dried preparations are provided by the Sichuan Institute of antibiotics, divided into two groups, (1) midecamycin tartrate group (tartaric acid